List of Excipients in Branded Drug ELIQUIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	ELIQUIS	apixaban	0003-0893	ANHYDROUS LACTOSE
ER Squibb & Sons LLC	ELIQUIS	apixaban	0003-0893	CELLULOSE, MICROCRYSTALLINE
ER Squibb & Sons LLC	ELIQUIS	apixaban	0003-0893	CROSCARMELLOSE SODIUM
ER Squibb & Sons LLC	ELIQUIS	apixaban	0003-0893	FERRIC OXIDE YELLOW
ER Squibb & Sons LLC	ELIQUIS	apixaban	0003-0893	HYPROMELLOSE
ER Squibb & Sons LLC	ELIQUIS	apixaban	0003-0893	LACTOSE MONOHYDRATE
ER Squibb & Sons LLC	ELIQUIS	apixaban	0003-0893	MAGNESIUM STEARATE

Eliquis Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Eliquis (apixaban) is a high-volume, small-molecule oral anticoagulant with a relatively conventional immediate-release tablet formulation. Its commercial value for excipient suppliers is concentrated in direct generic substitution, bioequivalence support, supply-chain qualification, taste and swallowability improvements, and formulation development for new dosage forms. The branded product uses widely available excipients, so the strongest opportunities are based on quality, consistency, regulatory support, and manufacturing performance rather than exclusive access to a proprietary excipient.

Executive summary: Eliquis tablets contain anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate in the tablet core. The film coating contains hypromellose, lactose monohydrate, titanium dioxide, triacetin, and iron oxides. The formulation is technically accessible to generic manufacturers, but apixaban’s narrow therapeutic context, low dose, dissolution sensitivity, and patent settlements delay broad U.S. generic competition. Excipient suppliers can target formulation equivalence, low-dose content uniformity, dissolution control, coating performance, pediatric delivery, and regional generic markets.

What excipients are used in Eliquis tablets?

The U.S. prescribing information identifies the inactive ingredients in Eliquis tablets as follows:

Formulation component	Excipient	Likely functional role
Tablet core	Anhydrous lactose	Diluent and bulking agent
Tablet core	Microcrystalline cellulose	Filler, dry binder, compressibility aid
Tablet core	Croscarmellose sodium	Superdisintegrant
Tablet core	Sodium lauryl sulfate	Wetting agent and dissolution aid
Tablet core	Magnesium stearate	Lubricant
Film coating	Hypromellose	Film former
Film coating	Lactose monohydrate	Coating filler or opacity modifier
Film coating	Titanium dioxide	Opacifier and whitening agent
Film coating	Triacetin	Plasticizer
Film coating	Iron oxide	Colorant

The 2.5 mg tablet is yellow and the 5 mg tablet is pink. The color difference is achieved through iron oxide pigments in the coating system. The formulation is an immediate-release, film-coated tablet rather than a modified-release or gastro-resistant product.[1]

The key technical feature is the low apixaban drug load. The active pharmaceutical ingredient represents a small fraction of the total tablet mass, increasing the importance of blending uniformity, segregation control, particle-size management, and validated sampling.

How does the Eliquis formulation affect generic development?

Generic developers must demonstrate pharmaceutical equivalence and bioequivalence through the ANDA pathway. For a conventional immediate-release tablet, the formulation does not need to duplicate every excipient at the same qualitative and quantitative level, but the product must meet applicable FDA requirements for dosage form, strength, quality, performance, and bioequivalence.[2]

The principal formulation risks are:

Low-dose content uniformity

Apixaban is present at 2.5 mg or 5 mg per tablet. Small changes in API particle size, density, electrostatic behavior, or blending time can affect content uniformity. Excipient systems with controlled particle-size distributions and low segregation potential are commercially relevant.

Microcrystalline cellulose and lactose are common diluents, but their grade selection can alter flow, compaction, tablet porosity, and disintegration. Co-processed excipients may reduce process variability, although the generic sponsor must establish compatibility and regulatory acceptability.

Dissolution performance

Sodium lauryl sulfate acts as a wetting agent and may improve dispersion of apixaban. Croscarmellose sodium promotes tablet breakup. Changes in lubricant concentration, blending time, compression force, or tablet hardness can change dissolution behavior.

For a generic manufacturer, the excipient system must support a dissolution profile sufficiently close to the reference product. The commercial opportunity is not simply to supply a low-cost excipient. It is to supply a grade with robust performance across manufacturing sites and scale.

Lubrication control

Magnesium stearate is necessary for ejection and tooling protection, but excessive lubrication can reduce tablet strength or slow wetting and dissolution. Supplier value can arise from tight control of specific surface area, fatty-acid composition, particle size, and batch consistency.

Film-coating reproducibility

Eliquis uses a colored film coat. A generic sponsor must match the relevant product appearance and maintain coating uniformity without creating defects, weight variation, or dissolution changes.

Hypromellose, triacetin, titanium dioxide, lactose, and iron oxides are established coating materials. Opportunities include ready-to-use coating systems, low-dust pigments, improved suspension stability, and coating platforms that reduce spray time and cleaning requirements.

What excipient strategies can support Eliquis generics?

The most commercially credible strategies fall into four categories.

Reference-like formulation strategy

A generic manufacturer can use the same excipient classes identified in the Eliquis label:

• Lactose plus microcrystalline cellulose as the diluent system
• Croscarmellose sodium as the disintegrant
• Sodium lauryl sulfate as the wetting agent
• Magnesium stearate as the lubricant
• Hypromellose-based colored film coating

This approach reduces formulation risk and simplifies excipient qualification. It does not, however, guarantee bioequivalence or freedom from process-related dissolution differences.

Co-processed excipient strategy

A co-processed filler-binder or filler-disintegrant can improve flow, compactibility, and content uniformity. This is most relevant where the generic manufacturer wants to reduce the number of raw materials or operate at high-speed compression.

The commercial limitation is regulatory comparability. A novel co-processed excipient may require more characterization than a conventional lactose-cellulose system. It may also increase supplier dependence if only one manufacturer has a qualified grade.

Surfactant and wetting optimization

Sodium lauryl sulfate is a direct formulation target because its level and distribution can affect wetting and dissolution. Alternative wetting agents may be technically possible, but each change creates additional formulation and regulatory work.

Suppliers can differentiate through:

• Low-peroxide and low-impurity grades
• Controlled particle size
• Consistent surface activity
• Improved handling and reduced dust
• Compatibility data with apixaban and tablet excipients

Film-coating platform strategy

A ready-to-use coating premix can reduce development time and improve color matching. The opportunity is stronger for manufacturers supplying multiple generic strengths or markets because one coating platform can be adapted across 2.5 mg and 5 mg tablets.

Coating suppliers should address titanium dioxide regulatory restrictions in particular markets. The European Union banned titanium dioxide as a food additive in 2022, but pharmaceutical use remains governed by pharmaceutical-specific rules and national implementation. Suppliers must therefore maintain region-specific regulatory files and alternative opacifier options.[3]

What patents protect Eliquis and its formulation?

The principal U.S. compound patent historically associated with Eliquis is U.S. Patent No. 6,967,208, covering apixaban-related compounds. Publicly reported U.S. patent information identifies February 2026 as the core patent expiration period, subject to applicable patent-term adjustment, pediatric exclusivity, regulatory exclusivity, and litigation settlements.[4]

The commercial position is more complicated than the nominal compound-patent date.

Issue	Commercial relevance
Active ingredient	Apixaban is a small molecule and can be copied through an ANDA
Core compound patent	Historically protected U.S. Eliquis commercialization through February 2026
Formulation patents	Must be reviewed separately in the Orange Book and litigation record
Method-of-use patents	May cover prevention of stroke and systemic embolism in atrial fibrillation or treatment and prevention of venous thromboembolism
Excipient composition	The listed excipients themselves are generally commodity materials and do not create a standalone Eliquis monopoly
Generic settlement terms	Can delay commercial launch beyond nominal patent expiration
International rights	Expiration dates and settlement effects vary by country

Excipient suppliers should not assume that supplying a conventional lactose, cellulose, disintegrant, lubricant, or coating system creates infringement exposure. Patent risk turns on the claims of asserted patents and the generic product’s formulation, process, labeling, and use. A supplier may still become relevant to discovery or indemnity discussions if its technical documents identify a formulation or manufacturing step covered by an asserted claim.

What is the Orange Book status of Eliquis?

Eliquis is an FDA-approved small-molecule drug listed in the Orange Book. Generic competition proceeds through ANDAs rather than biosimilar applications. FDA Orange Book listings identify patents and regulatory exclusivities associated with approved products, but the Orange Book does not determine whether a generic formulation infringes every potentially relevant patent.[5]

Eliquis is not a biologic. Biosimilar risk is therefore not applicable. The relevant competitive pathway is generic apixaban, including conventional tablets and any authorized generic arrangement.

The regulatory analysis should separate:

1. Orange Book-listed patents
2. Unlisted process or manufacturing patents
3. Method-of-use patents
4. Patent-term extensions and pediatric exclusivity
5. Paragraph IV certifications
6. Settlement-based launch restrictions

Which companies are challenging Eliquis exclusivity?

Multiple generic manufacturers have pursued or evaluated apixaban through ANDA filings and patent litigation. Public reporting has identified major generic companies, including Teva Pharmaceutical Industries, Sandoz, Apotex, Zydus, Micro Labs, and other ANDA sponsors, in connection with Eliquis patent challenges and settlements.

The most important commercial development was the settlement structure reported by Bristol Myers Squibb and Pfizer with generic manufacturers. Public company disclosures indicate that several generic companies agreed to launch restrictions that can extend U.S. generic entry into December 2028, despite the earlier nominal expiration of the core compound patent.[6][7]

Because settlement terms can differ by company, an excipient supplier should assess each potential customer’s:

• Authorized launch date
• Paragraph IV litigation status
• ANDA approval status
• Site readiness
• Expected launch volume
• Planned strengths and pack sizes
• Whether the customer will launch under its own label or through an authorized generic arrangement

When does Eliquis lose exclusivity?

The core U.S. patent protection is generally reported to expire in February 2026. Commercial generic entry may occur later because of patent litigation settlements and any remaining regulatory protections. Publicly disclosed settlement terms have pointed to December 1, 2028, for certain generic launches.[4][6]

Timeline	Event
2012	FDA approval of Eliquis for selected cardiovascular and thromboembolic indications
February 2026	Reported core U.S. patent expiration period
December 2028	Publicly reported settlement-based launch date for certain generic companies
Post-launch period	Price erosion, multi-source competition, reformulation, and regional expansion

The practical procurement window for excipient suppliers may begin before launch. Generic companies typically complete formulation lock, exhibit batches, process validation, stability work, and commercial sourcing well before the first commercial shipment.

What commercial opportunities exist for excipient suppliers?

Direct supply to generic apixaban manufacturers

The largest opportunity is supply of established excipients used in the reference product or in bioequivalent alternatives. The target categories are:

• Pharmaceutical-grade lactose
• Microcrystalline cellulose
• Croscarmellose sodium
• Sodium lauryl sulfate
• Magnesium stearate
• Hypromellose
• Triacetin
• Titanium dioxide or approved alternatives
• Yellow and red iron oxide pigments

Supplier selection will depend on global regulatory status, DMF support where relevant, GMP history, dual sourcing, and capacity assurance.

Formulation-development services

Excipient manufacturers can generate higher margins by offering application laboratories, prototype formulations, compaction studies, dissolution mapping, and scale-up support. A supplier with data on apixaban compatibility can reduce customer development time.

The most valuable data packages would cover:

• API-excipient compatibility
• Blend uniformity
• Tablet tensile strength
• Disintegration and dissolution
• Lubrication sensitivity
• Coating color and opacity
• Stability under accelerated conditions
• Multiple manufacturing scales

Pediatric and geriatric delivery

Eliquis is marketed as a tablet. Pediatric patients, patients with dysphagia, and patients requiring administration through enteral systems may create opportunities for orally dispersible, multiparticulate, liquid, or sprinkle formulations.

These products face greater regulatory and patent complexity than a standard generic tablet. They also require attention to dose flexibility, chemical stability, palatability, tube compatibility, sedimentation, and dose recovery. Taste-masking excipients and dispersible matrix systems are potential development areas.

Regional formulation adaptation

Excipient strategies can differ by geography because of local requirements for titanium dioxide, colorants, lactose, animal-derived materials, and elemental impurities. Suppliers with region-specific compliance packages can support launches in:

• United States
• European Union
• Japan
• Canada
• Latin America
• India and other emerging generic markets

Geographic diversification is important because the U.S. launch date may be delayed by settlements while other markets become accessible earlier.

How strong is the Eliquis excipient patent estate?

The excipient patent position is weaker than the active-ingredient patent position because the marketed product uses established excipient classes. A supplier’s defensible advantage is more likely to come from:

• Proprietary co-processed excipients
• Controlled particle engineering
• Ready-to-use coating systems
• Manufacturing know-how
• Regulatory documentation
• Supply reliability
• Customer-specific technical agreements

A formulation patent could create risk if it claims a specific apixaban-excipient combination, concentration range, particle-size relationship, or manufacturing process. A conventional product that uses the same inactive-ingredient categories is not automatically covered by the same claims.

The strongest commercial moat is therefore operational rather than purely patent-based. Suppliers that qualify early with multiple generic sponsors may capture launch demand, while suppliers that wait for post-expiration tenders may face rapid price compression.

What generic launch risks exist for Eliquis?

The main risks are timing, price erosion, and formulation substitution.

Risk	Effect on excipient opportunity
Settlement delays	Defers large-volume U.S. demand
Multiple generic entrants	Compresses excipient pricing
Authorized generic launch	May accelerate price erosion
Reference-like formulation competition	Favors established excipient grades
Alternative formulations	Creates higher-value technical opportunities
Manufacturing disruption	Increases value of dual-source suppliers
Regulatory changes	May require alternative coating or color systems
Low tablet dose	Raises content-uniformity and process-control demands

Eliquis has substantial revenue exposure for Bristol Myers Squibb and Pfizer. Pfizer reported approximately $7.7 billion in 2024 Eliquis revenue, while Bristol Myers Squibb reported approximately $7.4 billion, producing combined alliance revenue of roughly $15 billion.[6][7] That revenue base creates strong incentives for settlement management, authorized generic planning, lifecycle management, and supply-chain control.

How does Eliquis compare with competing anticoagulants?

Product	Active ingredient	Dosage form	Generic or biosimilar pathway	Excipient opportunity
Eliquis	Apixaban	Immediate-release tablet	ANDA	High-volume conventional tablet and pediatric development
Xarelto	Rivaroxaban	Tablet and oral suspension	ANDA	Solid and liquid formulation opportunities
Pradaxa	Dabigatran etexilate	Capsule	ANDA	Capsule-shell, moisture-control, and stability systems
Savaysa	Edoxaban	Tablet	ANDA	Smaller-volume tablet opportunity
Warfarin	Warfarin sodium	Tablet	ANDA	Mature, price-sensitive market

Eliquis is attractive because of its large revenue base and technically straightforward tablet form. Xarelto may offer broader dosage-form opportunities, while Pradaxa creates more specialized capsule and moisture-protection requirements. Eliquis remains the largest near-term excipient opportunity by potential generic volume, but it is also likely to face intense price competition.

Key Takeaways

• Eliquis uses a conventional immediate-release film-coated tablet formulation.
• Core excipients are anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.
• The coating uses hypromellose, lactose monohydrate, titanium dioxide, triacetin, and iron oxides.
• Low apixaban loading makes blend uniformity, segregation control, and dissolution performance central development issues.
• The core U.S. patent is generally reported to expire in February 2026, but settlements may delay certain generic launches until December 2028.
• Biosimilar competition is irrelevant because apixaban is a small molecule.
• The strongest supplier opportunities are formulation-grade excipients, ready-to-use coatings, co-processed excipients, pediatric delivery systems, and regulatory support.
• Conventional excipients offer limited patent exclusivity; supply reliability, technical data, and early customer qualification are more important commercial defenses.
• Combined Bristol Myers Squibb and Pfizer Eliquis revenue was approximately $15 billion in 2024, creating substantial generic and supplier interest.

FAQs

Can a generic Eliquis manufacturer use different excipients?

Yes. An ANDA applicant generally may use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, quality, and performance.

Is sodium lauryl sulfate essential to an apixaban generic?

No. It is used in the reference formulation, but a generic developer may evaluate alternative wetting systems. Any change must be supported by formulation, dissolution, stability, and regulatory data.

Are Eliquis excipients protected by patents?

The individual excipients are established pharmaceutical materials and generally do not create an Eliquis-specific monopoly. Risk depends on the claims of any applicable formulation or process patent.

Can excipient suppliers sell to Eliquis generic developers before U.S. launch?

Yes. Suppliers can qualify materials during formulation development, exhibit-batch manufacturing, process validation, and stability programs before the authorized commercial launch date.

Is a liquid apixaban product a biosimilar to Eliquis?

No. Apixaban is a small molecule. A liquid or orally dispersible apixaban product would use an ANDA, 505(b)(2), or another applicable small-molecule pathway rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). Eliquis (apixaban) prescribing information. Bristol-Myers Squibb Company and Pfizer Inc.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/generic-drugs

3. European Commission. (2022). Commission Regulation (EU) 2022/63 concerning titanium dioxide in food products. Official Journal of the European Union.

4. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 6,967,208: Nitrogen-containing heterobicyclic compounds and salts thereof.

5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

6. Bristol-Myers Squibb Company. (2025). 2024 annual report. https://www.bms.com

7. Pfizer Inc. (2025). 2024 annual report. https://www.pfizer.com/about/investors/financial-reports/annual-reports